France Daily Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on France Daily Times.

Press releases published on April 22, 2026

Apr. 22, 2026

Altimetrik Partners with Google Cloud to Scale Enterprise AI

Indeterminate EIN Presswire

Apr. 22, 2026

Thai Union Group Joins Protecting Blue Whales & Blue Skies to Advance More Responsible Shipping on California Coast

Indeterminate EIN Presswire

Apr. 22, 2026

ISTITUTO MARANGONI MILANO DESIGN WINS THE FENDI DESIGN PRIZE 2026 AND PRESENTS 'DESIGN AWAKENS' AT MILAN DESIGN WEEK

Indeterminate EIN Presswire

Apr. 22, 2026

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Indeterminate GlobeNewswire

Apr. 22, 2026

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée

Indeterminate GlobeNewswire

Apr. 22, 2026

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Indeterminate GlobeNewswire

Apr. 22, 2026

Nudie Jeans s’attaque à la fast fashion avec l’ouverture d’un store dans le Marais le 23 avril

Indeterminate EIN Presswire

Apr. 22, 2026

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Indeterminate GlobeNewswire

Apr. 22, 2026

Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor

Indeterminate GlobeNewswire

Apr. 22, 2026

Inventiva renforce son équipe de direction à l’approche des résultats de Phase 3 du lanifibranor

Indeterminate GlobeNewswire

Apr. 22, 2026

NETRIS Pharma: Nature publishes positive pancreatic cancer Phase 1b data for NP137 anti-netrin-1 monoclonal antibody

Indeterminate GlobeNewswire

Apr. 22, 2026

IMA Financial Group Places $4 Billion Property Insurance Program for AI Data Center

Indeterminate GlobeNewswire

Apr. 22, 2026

Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program

Indeterminate GlobeNewswire

Apr. 22, 2026

Elkedonia strengthens Board of Directors with appointment of Pierre d’Epenoux as Independent Chairman

Indeterminate GlobeNewswire

Apr. 22, 2026

Elkedonia renforce son Comité stratégique avec la nomination de Pierre d'Epenoux comme Président indépendant

Indeterminate GlobeNewswire

Apr. 22, 2026

Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

Indeterminate GlobeNewswire

Apr. 22, 2026

Communiqué de presse : Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants

Indeterminate GlobeNewswire

Apr. 22, 2026

Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

Indeterminate GlobeNewswire

Apr. 22, 2026

Ojemda® approuvé dans l’Union européenne comme première thérapie ciblée pour les enfants atteints de gliome pédiatrique de bas grade (pLGG), en rechute ou réfractaire, indépendamment de l’altération de BRAF

Indeterminate GlobeNewswire

Apr. 22, 2026

Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

Indeterminate GlobeNewswire